Novartis long-term Phase III data show Ph+ CML patients on Tasigna® achieved significantly deeper molecular response versus Glivec®
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
List view / Grid view
10 December 2012 | By Novartis
Latest results from two Phase III clinical trials...
4 December 2012 | By Novartis
Healthcare experts assess psychosocial approaches and interventions...
28 November 2012 | By Novartis
More than 140 presentations on key data...
20 November 2012 | By Novartis
The US FDA approved the use of Flucelvax®...
16 November 2012 | By Novartis
The CHMP of the EMA adopted a positive opinion for Exjade®...
16 November 2012 | By Novartis
The CHMP of the EMA has adopted a positive opinion for Bexsero for use in individuals from 2 months of age and older...
12 November 2012 | By Novartis
New two-year results...
11 November 2012 | By Novartis
New data from two Phase II trials of ACZ885...
8 November 2012 | By Novartis
Update on leading R&D pipeline...
7 November 2012 | By Novartis
Committee votes unanimously in favor of Signifor (pasireotide)...
7 November 2012 | By Novartis
RELAX-AHF study met one of its two primary endpoints...
5 November 2012 | By Novartis
European Commission approval for Votubia®...
1 November 2012 | By Edelman
NEJM published results...
31 October 2012 | By Novartis
Novartis announced the construction of a new state-of-the-art biotechnology production site...
31 October 2012 | By Novartis
Novartis welcomes the decisions by Health Canada and Swiss Agency for Therapeutic Products, Swissmedic...